|
Re: balancing herceptin's survival benefit vs cardiac toxicity (with STATISTICS)
Lani,
As always, thank you for this post as so many new members who join us are greatly concerned as they learn and glean information on Her2 breast cancer. It is overwhelming between hearing ones dx. and making life altering decisions.
Keeping in mind that women at higher risk of recurrence and in good health without signs of a weak heart, herceptin offers more benefits than risks.
Since most treatment decisions are based on results of clinical trials and studies...I am wondering was this trial done on patients who had A/C chemo?
Since we now know that A/C and herceptin has the the higher risk, especially when given together (which dr. are not doing anymore) A/C is given first than herceptin after.
In the study that Dr. Salmon did on TCH / v/ A/C that trial study had no heart issues with the TCH arm.
jean
__________________
Stage 1, Grade 1, 3/30/05
Lumpectomy 4/15/05 - 6MM IDC
Node Neg. (Sentinel node)
ER+ 90% / PR-, Her2+++ by FISH
Ki-67 40%
Arimidex 5/05
Radiation 32 trt, 5/30/05
Oncotype DX test 4/17/06, 31% high risk
TOPO 11 neg. 4/06
Stopped Arimidex 5/06
TCH 5/06, 6 treatments
Herceptin 5/06 - for 1 yr.
9/06 Completed chemo
Started Femara Sept. 2006
Last edited by Jean; 05-01-2012 at 05:51 AM..
|
Threaded Mode